Related Experiment Video

Updated: Mar 11, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Management of chronic hepatitis C in 2017

Leona von Köckritz, Jean-François Dufour1

  • 1Prof. Dr. med. Jean-François Dufour, MD, Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Freiburgstrasse, 3010 Bern, Switzerland, Phone: +41316328026; Fax: +41316327489,

Hamostaseologie
|November 30, 2016
PubMed

Insights

Hepatitis C virus (HCV) infection affects 80 million globally, often undiagnosed. Direct-acting antivirals offer a cure for most patients, improving management strategies for chronic liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) is a leading cause of chronic liver disease and a significant global health concern.
  • An estimated 80 million individuals worldwide are chronically infected, with a substantial portion remaining undiagnosed.
  • Untreated chronic HCV infection can progress to severe outcomes like cirrhosis, liver failure, and hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To provide comprehensive guidance on managing patients with chronic hepatitis C.
  • To outline recommendations for screening, diagnosis, clinical care, and treatment strategies.
  • To highlight the impact of direct-acting antivirals (DAAs) on achieving sustained virological response (SVR).

Main Methods:

  • This review synthesizes current knowledge on HCV management.
  • It incorporates recommendations for screening, diagnostic procedures, and clinical care.
  • It details treatment strategies utilizing direct-acting antivirals (DAAs) and follow-up protocols.

Main Results:

  • Direct-acting antivirals (DAAs) have significantly improved treatment efficiency and tolerability.
  • The majority of patients treated with recommended DAA combinations achieve a sustained virological response (SVR), indicating a cure.
  • Effective management includes early diagnosis, appropriate treatment, and diligent follow-up.

Conclusions:

  • Chronic hepatitis C management has been revolutionized by DAAs, offering high cure rates.
  • Comprehensive strategies encompassing screening, diagnosis, treatment, and follow-up are crucial for controlling HCV.
  • Improved patient outcomes and reduced global burden of liver disease are achievable with current therapeutic advancements.

Keywords:
direct-acting antiviralshepatitis C Virusrisk factorssustained virological response

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
452
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
599
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
707
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K